...
首页> 外文期刊>Journal of clinical gastroenterology >Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
【24h】

Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome

机译:一种新的联络粪便抗保护菌素测定的临床表现,从肠易肠综合征分化炎症性肠病

获取原文
获取原文并翻译 | 示例
           

摘要

Goal: The goal of this study was to assess the clinical performance of an investigational in vitro fecal calprotectin immunoassay for differentiating inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS). Background: Fecal calprotectin is a stool biomarker that can assist in the detection of intestinal inflammation and is utilized to identify individuals who have a higher chance of having IBD and who require further invasive tests. Current assays exhibit variable performance. Materials and Methods: This study was a multicenter, cross-sectional analysis of prospectively collected stool samples from patients 4 years of age or older who presented with gastrointestinal (GI) symptoms and underwent colonoscopy for diagnostic confirmation. IBD was diagnosed based on clinical, endoscopic, and histologic findings. IBS was diagnosed based on Rome III Criteria and negative colonoscopy. Stool samples were extracted and tested on the DiaSorin LIAISON XL using the LIAISON Calprotectin Assay. Results: A total of 240 patients (67% female) were included in the study. In total, 102 patients had IBD (54% ulcerative colitis), 67 had IBS, and 71 had other GI disorders. Median fecal calprotectin levels were significantly higher in patients with IBD [522?μg/g; 95% confidence interval (CI): 354-970?μg/g] compared with IBS (34.5?μg/g; 95% CI: 19.7-44.2?μg/g, P <0.001) and other GI disorders (28.6?μg/g; 95% CI: 18.7-40.3?μg/g, P <0.001). Receiver operating characteristic curve analysis indicated a fecal calprotectin cutoff of 94?μg/g for distinguishing IBD from other GI disorders with an area under the curve of 0.964 (sensitivity=92.2%, specificity=88.4%). Conclusion: The automated LIAISON Calprotectin assay brings efficient calprotectin testing to the laboratory with a time to the first result of 35 minutes and is a sensitive marker for distinguishing IBD from IBS with a cutoff of ~100?μg/g.
机译:目的:本研究的目的是评估体外粪便钙卫蛋白免疫分析的临床表现,以区分炎症性肠病(IBD)和肠易激综合征(IBS)。背景:粪便钙卫蛋白是一种粪便生物标记物,可以帮助检测肠道炎症,并用于识别IBD几率较高且需要进一步侵入性检测的个体。当前的分析显示出不同的性能。材料和方法:本研究是一项多中心、横断面分析,前瞻性收集了4岁或以上出现胃肠道(GI)症状并接受结肠镜检查以确诊的患者的粪便样本。根据临床、内镜和组织学检查结果诊断为IBD。IBS的诊断基于罗马III标准和阴性结肠镜检查。提取粪便样本,并在DiaSorin联络XL上使用联络钙卫蛋白分析进行测试。结果:共有240名患者(67%为女性)被纳入研究。总共有102名患者患有IBD(54%为溃疡性结肠炎),67名患者患有IBS,71名患者患有其他胃肠道疾病。IBD[522μg/g;95%可信区间(CI):354-970μg/g]患者的粪便钙卫蛋白中位数显著高于IBS(34.5μg/g;95%可信区间:19.7-44.2μg/g,P<0.001)和其他胃肠道疾病(28.6μg/g;95%可信区间:18.7-40.3μg/g,P<0.001)。受试者工作特征曲线分析表明粪便钙卫蛋白截止值为94?μg/g用于区分IBD和其他胃肠道疾病,其曲线下面积为0.964(敏感性=92.2%,特异性=88.4%)。结论:自动联用钙卫蛋白试验为实验室提供了有效的钙卫蛋白检测,首次检测结果的时间为35分钟,是区分IBD和IBS的敏感标志物,截止值为~100?μg/g。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号